CD248-CreERT2 conditional Yap1 knockout mice and human-derived ECM-CAF co-implantation models provided additional support that selectively disabling YAP1 in ECM-CAFs can slow prostate tumor growth, reduce matrix stiffness, and enhance responses to anti–PD-1 therapy [111]. This evidence concerns the gene YAP1 and prostate neoplasm.